The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Nanomedicine applied to translational oncology: A future perspective on cancer treatment
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552 · cited 1×
“Nanomaterials designed for cancer therapy can be as diverse as micelles, liposomes, dendrimers, inorganic nanoparticles, carbon nanoparticles and nanotubes, nanodiamonds, nanoemulsions, viral nanocarriers, polymeric or peptide nanoparticles, and solid lipid nanoparticles; they can self-assemble or be directly synthesi…”
BackgroundNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“Among the various types of nanomaterials developed for nanomedicine applications, liposomes and polymer-based nanoformulations constitute the majority of the nanotherapeutics approved for intravenous administration during cancer treatment (57-59).”
BackgroundFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Lundqvist, M., Stigler, J., Elia, G., Lynch, I., Cedervall, T., & Dawson, K. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805135105 · Cited by 2,823
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Hyperthermia in combined treatment of cancer
Wust, P., Hildebrandt, B., Sreenivasa, G., Rau, B., Gellermann, J., Riess, H., Felix, R., & Schlag, P. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00818-5 · Cited by 1,998
Walkey, C. D., & Chan, W. C. W. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15233e · Cited by 1,758
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
The cellular and molecular basis of hyperthermia
Hildebrandt, B. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00179-2 · Cited by 1,718
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Nanoshell-Enabled Photothermal Cancer Therapy: Impending Clinical Impact
Lal, S., Clare, S. E., & Halas, N. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar800150g · Cited by 1,625
Mediating Tumor Targeting Efficiency of Nanoparticles Through Design
Perrault, S. D., Walkey, C., Jennings, T., Fischer, H. C., & Chan, W. C. W. (2009) · Nano Letters · doi:10.1021/nl900031y · Cited by 1,513
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Time Evolution of the Nanoparticle Protein Corona
Casals, E., Pfaller, T., Duschl, A., Oostingh, G. J., & Puntes, V. (2010) · ACS Nano · doi:10.1021/nn901372t · Cited by 1,211
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173
Treating metastatic cancer with nanotechnology
Schroeder, A., Heller, D. A., Winslow, M. M., Dahlman, J. E., Pratt, G. W., Langer, R., Jacks, T., & Anderson, D. G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3180 · Cited by 1,159
Kim, B. Y. S., Rutka, J. T., & Chan, W. C. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912273 · Cited by 1,147
Mechanism of DNA Release from Cationic Liposome/DNA Complexes Used in Cell Transfection,
Xu, Y., & Szoka, F. C. (1996) · Biochemistry · doi:10.1021/bi9602019 · Cited by 1,134
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
The big picture on nanomedicine: the state of investigational and approved nanomedicine products
Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., & McCullough, J. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2012.05.013 · Cited by 1,088 · cited 4×
“macromolecular scale leading to the controlled creation and use of structures, devices and systems with a length scale of approximately 1–100 nm; (2) creating and using structures, devices, and systems, which have novel properties and functions as a result of their small and/or intermediate size; and (3) ability to co…”
BackgroundMethodInfluentialChauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031
Vinci, M., Gowan, S., Boxall, F., Patterson, L., Zimmermann, M., Court, W., Lomas, C., Mendiola, M., Hardisson, D., & Eccles, S. A. (2012) · BMC Biology · doi:10.1186/1741-7007-10-29 · Cited by 1,024 · cited 1×
“3D tumor spheroids have been recently proposed as the “standard-to-be” for development and optimization of new chemotherapeutic agents (150, 151).”
BackgroundTargeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway
Qian, Z. M., Li, H., Sun, H., & Ho, K. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.4.561 · Cited by 1,019
Polyethylenimine-based non-viral gene delivery systems
Lungwitz, U., Breunig, M., Blunk, T., & Göpferich, A. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.11.011 · Cited by 983
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J. F. W., & Hennink, W. E. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0233-4 · Cited by 947
Tenzer, S., Docter, D., Rosfa, S., Wlodarski, A., Kuharev, J., Rekik, A., Knauer, S. K., Bantz, C., Nawroth, T., Bier, C., et al. (2011) · ACS Nano · doi:10.1021/nn201950e · Cited by 856
Applications of gold nanoparticles in cancer nanotechnology
Cai, W. (2008) · Nanotechnology, Science and Applications · doi:10.2147/nsa.s3788 · Cited by 851
Strategies for advancing cancer nanomedicine
Chauhan, V. P., & Jain, R. K. (2013) · Nature Materials · doi:10.1038/nmat3792 · Cited by 812
The nanosilica hazard: another variable entity
Napierska, D., Thomassen, L. C., Lison, D., Martens, J. A., & Hoet, P. H. (2010) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-7-39 · Cited by 806
Fadeel, B., & Garcia-Bennett, A. E. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.008 · Cited by 783
Progress in developing cationic vectors for non-viral systemic gene therapy against cancer
Morille, M., Passirani, C., Vonarbourg, A., Clavreul, A., & Benoit, J.-P. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.04.036 · Cited by 769
The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles
Cho, E. C., Zhang, Q., & Xia, Y. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.58 · Cited by 719
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers
Gu, F., Zhang, L., Teply, B. A., Mann, N., Wang, A., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711714105 · Cited by 715
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
Libutti, S. K., Paciotti, G. F., Byrnes, A. A., Alexander, H. R., Gannon, W. E., Walker, M., Seidel, G. D., Yuldasheva, N., & Tamarkin, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0978 · Cited by 710
Subcellular targeting strategies for drug design and delivery
Rajendran, L., Knölker, H.-J., & Simons, K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2897 · Cited by 708
Microfluidic technologies for accelerating the clinical translation of nanoparticles
Valencia, P. M., Farokhzad, O. C., Karnik, R., & Langer, R. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.168 · Cited by 698
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
Green, M. D., Koelbl, H., Baselga, J., Galid, A., Guillem, V., Gascon, P., Siena, S., Lalisang, R. I., Samonigg, H., Clemens, M. R., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg019 · Cited by 586
Nanodiamond Therapeutic Delivery Agents Mediate Enhanced Chemoresistant Tumor Treatment
Chow, E. K., Zhang, X.-Q., Chen, M., Lam, R., Robinson, E., Huang, H., Schaffer, D., Osawa, E., Goga, A., & Ho, D. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001713 · Cited by 556
Nanomedicines: addressing the scientific and regulatory gap
Tinkle, S., McNeil, S. E., Mühlebach, S., Bawa, R., Borchard, G., Barenholz, Y. (., Tamarkin, L., & Desai, N. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12403 · Cited by 546
Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics
Klumpp, C., Kostarelos, K., Prato, M., & Bianco, A. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2005.10.008 · Cited by 540
Cancer nanomedicines: So many papers and so few drugs!
Venditto, V. J., & Szoka, F. C. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.038 · Cited by 537
Dawidczyk, C. M., Kim, C., Park, J. H., Russell, L. M., Lee, K. H., Pomper, M. G., & Searson, P. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.036 · Cited by 527
Sparreboom, A., Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A., Beals, B., Figg, W. D., Hawkins, M., & Desai, N. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2291 · Cited by 504
Targeted therapy using nanotechnology: focus on cancer
Sechi, M., Sanna, V., & Pala, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s36654 · Cited by 493
Dromi, S., Frenkel, V., Luk, A., Traughber, B., Angstadt, M., Bur, M., Poff, J., Xie, J., Libutti, S. K., Li, K. C. P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2443 · Cited by 492
Management and Preparedness for Infusion and Hypersensitivity Reactions
Lenz, H.-J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-601 · Cited by 479 · cited 1×
“Owing to its longer half-life, it often takes fewer administrations of Oncaspar to achieve a therapeutic effect similar to that of the native enzyme (84).”
BackgroundSelf-Assembled Targeted Nanoparticles: Evolution of Technologies and Bench to Bedside Translation
Shi, J., Xiao, Z., Kamaly, N., & Farokhzad, O. C. (2011) · Accounts of Chemical Research · doi:10.1021/ar200054n · Cited by 476
Silverman, J. A., & Deitcher, S. R. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2042-4 · Cited by 474
Magnetic nanoparticle hyperthermia for prostate cancer
Johannsen, M., Thiesen, B., Wust, P., & Jordan, A. (2010) · International Journal of Hyperthermia · doi:10.3109/02656731003745740 · Cited by 469
Stylianopoulos, T., Poh, M.-Z., Insin, N., Bawendi, M. G., Fukumura, D., Munn, L. L., & Jain, R. K. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2010.06.016 · Cited by 443
Zuckerman, J. E., Gritli, I., Tolcher, A., Heidel, J. D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M. E., & Yen, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411393111 · Cited by 427
Development of in vitro systems for nanotoxicology: methodological considerations
Stone, V., Johnston, H., & Schins, R. P. F. (2009) · Critical Reviews in Toxicology · doi:10.1080/10408440903120975 · Cited by 427
Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice.
Thurston, G., McLean, J. W., Rizen, M., Baluk, P., Haskell, A., Murphy, T. J., Hanahan, D., & McDonald, D. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci965 · Cited by 423
3D tumour models: novel in vitro approaches to cancer studies
Nyga, A., Cheema, U., & Loizidou, M. (2011) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-011-0132-4 · Cited by 407
Nanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
Nanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies
Cho, E. J., Holback, H., Liu, K. C., Abouelmagd, S. A., Park, J., & Yeo, Y. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300697h · Cited by 382
Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepulveda, J., Burrone, O., Neri, D., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10662 · Cited by 355
Modeling the Time Evolution of the Nanoparticle-Protein Corona in a Body Fluid
Dell'Orco, D., Lundqvist, M., Oslakovic, C., Cedervall, T., & Linse, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010949 · Cited by 337
Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel
Danhier, F., Vroman, B., Lecouturier, N., Crokart, N., Pourcelle, V., Freichels, H., Jérôme, C., Marchand-Brynaert, J., Feron, O., & Préat, V. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.08.011 · Cited by 335
Nanomaterials for Cancer Therapy and Imaging
Bae, K. H., Chung, H. J., & Park, T. G. (2011) · Molecules and Cells · doi:10.1007/s10059-011-0051-5 · Cited by 313
Personalized protein coronas: a “key” factor at the nanobiointerface
Hajipour, M. J., Laurent, S., Aghaie, A., Rezaee, F., & Mahmoudi, M. (2014) · Biomaterials Science · doi:10.1039/c4bm00131a · Cited by 307
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9399-1 · Cited by 303
Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells
Wang, S., & Low, P. S. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00236-8 · Cited by 295
Nanotherapeutics in the EU: an overview on current state and future directions
Pepic, I., Hafner, A., Lovric, J., & Perina Lakos, G. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s55359 · Cited by 294
Newman, M. S., Colbern, G. T., Working, P. K., Engbers, C., & Amantea, M. A. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050855 · Cited by 275
Biomedical applications of functionalized fullerene-based nanomaterials
Conyers, J. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s5964 · Cited by 274
Crist, R. M., Grossman, J. H., Patri, A. K., Stern, S. T., Dobrovolskaia, M. A., Adiseshaiah, P. P., Clogston, J. D., & McNeil, S. E. (2013) · Integrative Biology · doi:10.1039/c2ib20117h · Cited by 265
Safety assessment of nanomaterials: Implications for nanomedicine
Nyström, A. M., & Fadeel, B. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.027 · Cited by 264
Dennis, C. L., Jackson, A. J., Borchers, J. A., Hoopes, P. J., Strawbridge, R., Foreman, A. R., van Lierop, J., Grüttner, C., & Ivkov, R. (2009) · Nanotechnology · doi:10.1088/0957-4484/20/39/395103 · Cited by 254
Advantages of liposomal delivery systems for anthracyclines
Allen, T. M., & Martin, F. J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.08.001 · Cited by 248
Ligand-Targeted Liposomes for Cancer Treatment
Sapra, P., Tyagi, P., & Allen, T. (2005) · Current Drug Delivery · doi:10.2174/156720105774370159 · Cited by 246
Waterhouse, D. N., Tardi, P. G., Mayer, L. D., & Bally, M. B. (2001) · Drug Safety · doi:10.2165/00002018-200124120-00004 · Cited by 242
Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials
Wang, R., Billone, P. S., & Mullett, W. M. (2013) · Journal of Nanomaterials · doi:10.1155/2013/629681 · Cited by 236
Targeting of albumin-embedded paclitaxel nanoparticles to tumors
Karmali, P. P., Kotamraju, V. R., Kastantin, M., Black, M., Missirlis, D., Tirrell, M., & Ruoslahti, E. (2009) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2008.07.007 · Cited by 234
Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents
Zamboni, W. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1895 · Cited by 234
McKim Jr., J. (2010) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620710790596736 · Cited by 231
Weiss, G. J., Chao, J., Neidhart, J. D., Ramanathan, R. K., Bassett, D., Neidhart, J. A., Choi, C. H. J., Chow, W., Chung, V., Forman, S. J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9921-8 · Cited by 230
Enabling individualized therapy through nanotechnology
Sakamoto, J. H., van de Ven, A. L., Godin, B., Blanco, E., Serda, R. E., Grattoni, A., Ziemys, A., Bouamrani, A., Hu, T., Ranganathan, S. I., et al. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2009.12.011 · Cited by 229
Evaluation of the Toxicity of Intravenous Delivery of Auroshell Particles (Gold–Silica Nanoshells)
Gad, S. C., Sharp, K. L., Montgomery, C., Payne, J. D., & Goodrich, G. P. (2012) · International Journal of Toxicology · doi:10.1177/1091581812465969 · Cited by 227
Gene delivery by cationic lipid vectors: overcoming cellular barriers
Zuhorn, I. S., Engberts, J. B. F. N., & Hoekstra, D. (2007) · European Biophysics Journal · doi:10.1007/s00249-006-0092-4 · Cited by 224
Feasibility Study of Particle-Assisted Laser Ablation of Brain Tumors in Orthotopic Canine Model
Schwartz, J. A., Shetty, A. M., Price, R. E., Stafford, R. J., Wang, J. C., Uthamanthil, R. K., Pham, K., McNichols, R. J., Coleman, C. L., & Payne, J. D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2535 · Cited by 222
Huang, S., Shao, K., Liu, Y., Kuang, Y., Li, J., An, S., Guo, Y., Ma, H., & Jiang, C. (2013) · ACS Nano · doi:10.1021/nn400548g · Cited by 212
Delivery of RNA interference therapeutics using polycation-based nanoparticles
Howard, K. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.001 · Cited by 211
Nanopharmacy: Inorganic nanoscale devices as vectors and active compounds
Rivera Gil, P., Hühn, D., del Mercato, L. L., Sasse, D., & Parak, W. J. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.009 · Cited by 202
Schmitt‐Sody, M., Strieth, S., Krasnici, S., Sauer, B., Schulze, B. G., Teifel, M., Michaelis, U., Naujoks, K., & Dellian, M. (2003) · PubMed · Cited by 192
Poon, R. T., & Borys, N. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802677874 · Cited by 189
The nano-plasma interface: Implications of the protein corona
Wolfram, J., Yang, Y., Shen, J., Moten, A., Chen, C., Shen, H., Ferrari, M., & Zhao, Y. (2014) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.02.035 · Cited by 188
Harrington, K. J., Lewanski, C. R., Northcote, A. D., Whittaker, J., Wellbank, H., Vile, R. G., Peters, A. M., & Stewart, J. S. W. (2001) · Annals of Oncology · doi:10.1023/a:1011199028318 · Cited by 182
E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children
Tallal, L., Tan, C., Oettgen, H., Wollner, N., McCarthy, M., Helson, L., Burchenal, J., Karnofsky, D., & Murphy, M. L. (1970) · Cancer · doi:10.1002/1097-0142(197002)25:2<306::aid-cncr2820250206>3.0.co;2-h · Cited by 174
Angst, M. S., & Drover, D. R. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645120-00002 · Cited by 173
Liu, G., Duan, G., Jia, L., Wang, J., Wang, H., Cai, W., & Li, Y. (2013) · Journal of Nanomaterials · doi:10.1155/2013/365947 · Cited by 168
Ehmann, F., Sakai-Kato, K., Duncan, R., Pérez de la Ossa, D. H., Pita, R., Vidal, J.-M., Kohli, A., Tothfalusi, L., Sanh, A., Tinton, S., et al. (2013) · Nanomedicine · doi:10.2217/nnm.13.68 · Cited by 160
Recent Advances and Patents on Solid Lipid Nanoparticles
Sawant, K. K., & Dodiya, S. S. (2008) · Recent Patents on Drug Delivery & Formulation · doi:10.2174/187221108784534081 · Cited by 158
Mifamurtide for the treatment of nonmetastatic osteosarcoma
Ando, K., Mori, K., Corradini, N., Rédiní, F., & Heymann, D. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.543129 · Cited by 155
Translational nanomedicine: status assessment and opportunities
Murday, J. S., Siegel, R. W., Stein, J. A., & Wright, J. F. (2009) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2009.06.001 · Cited by 155
The Upcoming Field of Theranostic Nanomedicine: An Overview
Prabhu, P. S., & Patravale, V. B. (2012) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2012.1459 · Cited by 153
FDA's Approach to Regulation of Products of Nanotechnology
Hamburg, M. A. (2012) · Science · doi:10.1126/science.1205441 · Cited by 152
White, S. C., Lorigan, P. C., Margison, G. P., Margison, J. M., Martin, F., Thatcher, N., Anderson, H., & Ranson, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603345 · Cited by 152
Emerging nanomaterials for targeting subcellular organelles
Huang, J. G., Leshuk, T. M. C., & Gu, F. (2011) · Nano Today · doi:10.1016/j.nantod.2011.08.002 · Cited by 150
Awada, A. H., Bondarenko, I., Bonneterre, J. M., Nowara, E., Ferrero, J.-M., Bakshi, A. V., Wilke, C., & Piccart, M. J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu025 · Cited by 142
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer
Kim, E. S., Lu, C., Khuri, F. R., Tonda, M. E., Glisson, B. S., Liu, D., Jung, M., Hong, W. K., & Herbst, R. S. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00278-1 · Cited by 136
Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma
Meyers, P. A. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.69 · Cited by 134
The design and development of DaunoXome® for solid tumor targeting in vivo
Forssen, E. A. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00453-x · Cited by 134
Challenges Posed by The Scale-Up of Nanomedicines
Muthu, M. S., & Wilson, B. (2012) · Nanomedicine · doi:10.2217/nnm.12.3 · Cited by 134
The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia
Fassas, Α., & Anagnostopoulos, Α. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500052438 · Cited by 134
Lipid-enveloped hybrid nanoparticles for drug delivery
Tan, S., Li, X., Guo, Y., & Zhang, Z. (2012) · Nanoscale · doi:10.1039/c2nr32880a · Cited by 134
Nardin, A., Lefebvre, M., Labroquère, K., Faure, O., & Abastado, J. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906776056473 · Cited by 133
Bio-Nanotechnology: A Revolution in Food, Biomedical and Health Sciences
Bagchi, D., Bagchi, M., Moriyama, H., & Shahidi, F. (2012) · Cited by 128
Blood protein coating of gold nanoparticles as potential tool for organ targeting
Schäffler, M., Sousa, F., Wenk, A., Sitia, L., Hirn, S., Schleh, C., Haberl, N., Violatto, M. B., Canovi, M., Andreozzi, P., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.100 · Cited by 128
O'Brien, M. E. R., Socinski, M. A., Popovich, A. Y., Bondarenko, I., Tomova, A., ̆ı, B. T. B., Hotko, Y., Ganul, V. L., Kostinsky, I. Y., Eisenfeld, A. J., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31817c6b68 · Cited by 125
Chen, N., Li, Y., Ye, Y., Palmisano, M., Chopra, R., & Zhou, S. Y. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.304 · Cited by 123
Kono, K., Nakashima, S., Kokuryo, D., Aoki, I., Shimomoto, H., Aoshima, S., Maruyama, K., Yuba, E., Kojima, C., Harada, A., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.10.050 · Cited by 123
Phuphanich, S., Maria, B., Braeckman, R., & Chamberlain, M. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9218-x · Cited by 122
Endo, K., Ueno, T., Kondo, S., Wakisaka, N., Murono, S., Itō, M., Kataoka, K., Kato, Y., & Yoshizaki, T. (2012) · Cancer Science · doi:10.1111/cas.12079 · Cited by 119
Löhr, M. J., Haas, S., Bechstein, W. O., Bodoky, G., Cwiertka, K., Fischbach, W., Fölsch, U. R., Jäger, D., Osinsky, D., Prausová, J., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr379 · Cited by 108
Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer.
Seetharamu, N., Kim, E., Höchster, H. S., Martin, F., & Muggia, F. M. (2010) · PubMed · Cited by 107
Translational considerations for cancer nanomedicine
Stern, S. T., Hall, J. B., Yu, L. L., Wood, L. J., Paciotti, G. F., Tamarkin, L., Long, S. E., & McNeil, S. E. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.008 · Cited by 99
Challenges to effective cancer nanotheranostics
Melancon, M. P., Stafford, R. J., & Li, C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.045 · Cited by 84
Electrostatic surface modifications to improve gene delivery
Shmueli, R. B., Anderson, D. G., & Green, J. J. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425241003603653 · Cited by 83
Delivering nanomedicines to patients: A practical guide
Eaton, M., Lévy, L., & Fontaine, O. M. A. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.02.004 · Cited by 77
Clift, M. J. D., & Stone, V. (2012) · Theranostics · doi:10.7150/thno.4545 · Cited by 73
Veal, G. J., Griffin, M. J., Price, E., Parry, A., Dick, G., Little, M., Yule, S. M., Morland, B. J., Estlin, E., Hale, J., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1723 · Cited by 69
Dendrimers as Biopharmaceuticals: Synthesis and Properties
Villalonga‐Barber, C., Micha‐Screttas, M., Steele, B. R., Georgopoulos, A., & Demetzos, C. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608785849012 · Cited by 65
Role of Nanobiotechnology in the Development of Personalized Medicine
Jain, K. (2009) · Nanomedicine · doi:10.2217/nnm.09.12 · Cited by 63
Sabbatini, P. J., Sill, M. W., O’Malley, D. M., Adler, L. M., & Secord, A. A. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.07.049 · Cited by 60
Jarrar, M., Gaynon, P. S., Periclou, A. P., Fu, C. H., Harris, R. E., Stram, D. O., Altman, A. J., Bostrom, B., Breneman, J. C., Steele, D., et al. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20713 · Cited by 54
Rosenthal, D. I., Yom, S. S., Liu, L., et al. (2002) · Investigational New Drugs · doi:10.1023/a:1016201732368 · Cited by 51
Nanotechnological Strategies for Therapeutic Targeting of Tumor Vasculature
Ding, Y., Li, S., & Nie, G. (2013) · Nanomedicine · doi:10.2217/nnm.13.106 · Cited by 51
FDA and Nanotech: Baby Steps Lead to Regulatory Uncertainty
Bawa, R. (2013) · Wiley eBooks · doi:10.1002/9781118451915.ch41 · Cited by 50
Ribeiro, J. M., Macedo, L. T., Curigliano, G., Fumagalli, L. A. M., Locatelli, M., Dalton, M., Quintela, A., Carvalheira, J. B. C., Manunta, S., Mazzarella, L., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr382 · Cited by 49
Do Nanomedicines Require Novel Safety Assessments to Ensure their Safety for Long-Term Human Use?
Hoet, P., Legiest, B., Geys, J., & Nemery, B. (2009) · Drug Safety · doi:10.2165/00002018-200932080-00002 · Cited by 48
Anderson, P. M. (2006) · Future Oncology · doi:10.2217/14796694.2.3.333 · Cited by 40
Tumor angiogenic endothelial cell targeting by a novel integrin-targeted nanoparticle.
Xie, J., Shen, Z., Li, K. C., & Danthi, N. S. (2007) · PubMed Central · Cited by 37
Treat, J., Damjanov, N., Huang, C., Zrada, S., & Rahman, A. (2001) · PubMed · Cited by 35
Taking Temperature — A Review of European Union Regulation in Nanomedicine
CALSTER, G. V., & D’Silva, J. (2009) · European Journal of Health Law · doi:10.1163/157180909x453071 · Cited by 35
Dorbeck-Jung, B. R., & Chowdhury, N. (2011) · Law & Policy · doi:10.1111/j.1467-9930.2011.00339.x · Cited by 33
Scope of Nanotechnology-based Radiation Therapy and Thermotherapy Methods in Cancer Treatment
Bakht, M. K., Sadeghi, M., Masouleh, M. P., & Tenreiro, C. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912803251216 · Cited by 33
Salvador-Morales, C., Khorasani, A. A., & Weaver, J. L. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s72479 · Cited by 31
RGD modified albumin nanospheres for tumour vasculature targeting
Dubey, P. K., Singodia, D., Verma, R. K., & Vyas, S. P. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01180.x · Cited by 30
New G-CSF agonists for neutropenia therapy
Hoggatt, J., & Pelus, L. M. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.838558 · Cited by 30
FDA approves liposomal vincristine (Marqibo) for rare leukemia.
Ingram, I. (2012) · PubMed · Cited by 21
Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
Pelus, L. M., Hoggatt, J., & Tate, T. A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s55796 · Cited by 19
Vokes, E. E., Gordon, G. S., Mauer, A. M., Rudin, C. M., Krauss, S. A., Szeto, L. L., Golomb, H. M., & Hoffman, P. C. (2000) · Clinical Lung Cancer · doi:10.3816/clc.2000.n.025 · Cited by 15
Design and Development of Approved Nanopharmaceutical Products
Bawa, R., Audette, G. F., & Rubinstein, I. (2016) · doi:10.1201/b19915-18 · Cited by 6
Cited by
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101
Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects
Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020) · Nanomaterials · doi:10.3390/nano10071403 · Cited by 1,061
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Sun, Q., Zhou, Z., Qiu, N., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606628 · Cited by 1,058
Cancer nanomedicine: A review of recent success in drug delivery
Tran, S., DeGiovanni, P., Piel, B., & Rai, P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0175-0 · Cited by 879
Innovative approaches for cancer treatment: current perspectives and new challenges
Pucci, C., Martinelli, C., & Ciofani, G. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.961 · Cited by 814
Metadata
- Authors
- Bregoli, L., Movia, D., Gavigan-Imedio, J. D., Lysaght, J., Reynolds, J., & Prina-Mello, A.
- Venue
- Nanomedicine: Nanotechnology, Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 12
- Issue
- 1
- Pages
- 81-103
- ISSN
- 1549-9634 (ISSN-L)
- OpenAlex
- W1860534622
- Cited by
- 296
- References
- 153
- FWCI
- 8.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.